The latest price target for Kymera Therapeutics (NASDAQ:KYMR) was reported by Morgan Stanley on August 14, 2024. The analyst firm set a price target for $45.00 expecting KYMR to fall to within 12 months (a possible -5.82% downside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Kymera Therapeutics (NASDAQ:KYMR) was provided by Morgan Stanley, and Kymera Therapeutics maintained their equal-weight rating.

The last upgrade for Kymera Therapeutics Inc happened on May 5, 2023 when Raymond James raised their price target to $38. Raymond James previously had a market perform for Kymera Therapeutics Inc.

The last downgrade for Kymera Therapeutics Inc happened on January 3, 2024 when B of A Securities changed their price target from $45 to $30 for Kymera Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kymera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kymera Therapeutics was filed on August 14, 2024 so you should expect the next rating to be made available sometime around August 14, 2025.

While ratings are subjective and will change, the latest Kymera Therapeutics (KYMR) rating was a maintained with a price target of $34.00 to $45.00. The current price Kymera Therapeutics (KYMR) is trading at is $47.78, which is out of the analyst’s predicted range.